A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 [chemokine (C-C motif) receptor 5] Antagonist (ADARC 2007-02).

Trial Profile

A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 [chemokine (C-C motif) receptor 5] Antagonist (ADARC 2007-02).

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2012

At a glance

  • Drugs Abacavir; Didanosine; Efavirenz; HIV protease inhibitors; Maraviroc; Nevirapine; Ritonavir; Tenofovir disoproxil fumarate; Zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2012 Actual patient number (8) added as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top